Objective Cancer is the second leading cause of death in European countries, and one of the most imminent health problems in the developed world. Innovative, so-called targeted therapies are urgently needed that aim specifically at cancer cells or to cells of the stroma that support tumor growth. The ultimate goal of a targeted therapy is to increase anti-tumor efficacy with lowest possible side effects. Rapid and efficient translation of basic scientific advances into reagents, and targeted molecular leads for preclinical and clinical research and development based on scientific rationales and state-of-the-art technologies, optimally requires an interdisciplinary, collaborative, team-oriented approach. EUCAAD represents a virtual research institute in Europe and consists of 9 research participants including 4 SMEs devoted to the discovery and evaluation of new antibodies for therapy of human cancers. The consortium consists of researchers from SMEs and scientific and clinical centres that have gained international acclaim in this area of research, many of who have worked together in previous EU funded applications e.g. ANGIOSTOP, EUCAPS, ESTDAB and ENACT. Within the consortium there is unique expertise regarding target discovery, target validation, antibody production and initiation of clinical trials. As part of its efforts to translate laboratory research into viable cancer therapies the individual partners has accumulated an extensive portfolio of intellectual property providing a competitive edge to this application. The focus of the grant is the development and evaluation of antibodies against new target structures on tumour cells and blood vessels supplying tumours which are responsible for tumour angiogenesis, progression and metastasis. Collectively, the activities of this consortium can improve the cancer treatment standards in Europe and provide economic benefit to European biotechnology and pharmaceutical research by providing novel immunopharmaceuticals. Fields of science medical and health sciencesclinical medicineoncology Keywords Antibodies angiogenesis angiomotin cancer clinical trials endothelial cells neovascularization tumour Programme(s) FP7-HEALTH - Specific Programme "Cooperation": Health Topic(s) HEALTH-2007-1.4-1 - Development and production of new generation antibodies Call for proposal FP7-HEALTH-2007-A See other projects for this call Funding Scheme CP-FP - Small or medium-scale focused research project Coordinator KAROLINSKA INSTITUTET EU contribution € 2 286 109,90 Address Nobels Vag 5 17177 Stockholm Sweden See on map Region Östra Sverige Stockholm Stockholms län Activity type Higher or Secondary Education Establishments Administrative Contact Maria Von Witting (Ms.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data Participants (8) Sort alphabetically Sort by EU Contribution Expand all Collapse all BIOINVENT INTERNATIONAL AB Sweden EU contribution € 1 068 920,00 Address SOELVEGATAN 41 22370 LUND See on map Region Södra Sverige Sydsverige Skåne län Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Administrative Contact Stefan Ericsson (Mr.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data UNIVERSITE D'AIX MARSEILLE France EU contribution € 532 098,00 Address BOULEVARD CHARLES LIVON 58 LE PHARO 13284 Marseille See on map Region Provence-Alpes-Côte d’Azur Provence-Alpes-Côte d’Azur Bouches-du-Rhône Activity type Higher or Secondary Education Establishments Administrative Contact Celine Damon (Ms.) Links Contact the organisation Opens in new window Total cost No data OXURION Participation ended Belgium EU contribution No data Address GASTON GEENSLAAN 1 3001 Leuven See on map Region Vlaams Gewest Prov. Vlaams-Brabant Arr. Leuven Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Administrative Contact Jean Marie Stassen (Dr.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data MARTIN-LUTHER-UNIVERSITAT HALLE-WITTENBERG Germany EU contribution € 425 361,00 Address UNIVERSITATSPLATZ 10 6108 Halle See on map Region Baden-Württemberg Stuttgart Stuttgart, Stadtkreis Activity type Higher or Secondary Education Establishments Administrative Contact Peter Waehner (Dr.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data UNIVERSITA DEGLI STUDI DI TORINO Italy EU contribution € 637 504,00 Address VIA GIUSEPPE VERDI 8 10124 Torino See on map Region Nord-Ovest Piemonte Torino Activity type Higher or Secondary Education Establishments Administrative Contact Eugenio Rinaldi (Dr.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data PHILOCHEM AG Switzerland EU contribution € 309 206,80 Address LIBERNSTRASSE 3 8112 Otelfingen See on map Region Schweiz/Suisse/Svizzera Zürich Zürich Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Administrative Contact Eveline Trachsel (Dr.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data PROTAGEN AG Germany EU contribution € 456 640,70 Address Otto-Hahn-Strasse 15 44227 DORTMUND See on map Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Administrative Contact Sven Rüger (Mr.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data UNIVERSITA DEGLI STUDI GABRIELE D'ANNUNZIO DI CHIETI-PESCARA Italy EU contribution € 274 021,60 Address Via dei Vestini 31 66013 Chieti See on map Region Sud Abruzzo Chieti Activity type Higher or Secondary Education Establishments Administrative Contact Luciana Gallo (Dr.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data